Full Product Name
CHD7 siRNA (Human)
Product Synonym Names
KIAA1416; Chromodomain-helicase-DNA-binding protein 7; CHD-7; ATP-dependent helicase CHD7
Product Gene Name
CHD7 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9P2D1
Specificity
CHD7 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CHD7 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CHD7 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CHD7 sirna
siRNA to inhibit CHD7 expression using RNA interference
Applications Tested/Suitable for CHD7 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CHD7. It may not necessarily be applicable to this product.
NCBI Accession #
NP_060250.2
[Other Products]
NCBI GenBank Nucleotide #
NM_017780.3
[Other Products]
UniProt Primary Accession #
Q9P2D1
[Other Products]
UniProt Secondary Accession #
Q05DI5; Q2TAN4; Q66K35; Q7Z6C0; Q7Z7Q2; Q9NXA0; Q9NXA3; D0VBA5; E9PNZ2[Other Products]
UniProt Related Accession #
Q9P2D1[Other Products]
Molecular Weight
101,085 Da
NCBI Official Full Name
chromodomain-helicase-DNA-binding protein 7
NCBI Official Synonym Full Names
chromodomain helicase DNA binding protein 7
NCBI Official Symbol
CHD7 [Similar Products]
NCBI Official Synonym Symbols
CRG; HH5; IS3; KAL5
[Similar Products]
NCBI Protein Information
chromodomain-helicase-DNA-binding protein 7
UniProt Protein Name
Chromodomain-helicase-DNA-binding protein 7
UniProt Synonym Protein Names
ATP-dependent helicase CHD7
Protein Family
Chromodomain-helicase-DNA-binding protein
UniProt Gene Name
CHD7 [Similar Products]
UniProt Synonym Gene Names
KIAA1416; CHD-7 [Similar Products]
UniProt Entry Name
CHD7_HUMAN
NCBI Summary for CHD7
This gene encodes a protein that contains several helicase family domains. Mutations in this gene have been found in some patients with the CHARGE syndrome. [provided by RefSeq, Jul 2008]
UniProt Comments for CHD7
CHD-7: Probable transcription regulator. May interact with CTCF. Interacts with CHD8. Widely expressed in fetal and ***** tissues. Belongs to the SNF2/RAD54 helicase family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 3.6.4.12; DNA-binding; Nucleolus; Helicase
Chromosomal Location of Human Ortholog: 8q12.2
Cellular Component: nucleoplasm; nucleolus; nucleus
Molecular Function: protein binding; DNA binding; chromatin binding; helicase activity; ATP binding
Biological Process: heart morphogenesis; limb development; central nervous system development; olfactory behavior; blood circulation; palate development; positive regulation of multicellular organism growth; female genitalia development; olfactory nerve development; embryonic hindlimb morphogenesis; regulation of growth hormone secretion; ***** walking behavior; sensory perception of sound; regulation of neurogenesis; regulation of transcription, DNA-dependent; skeletal development; T cell differentiation; ***** heart development; inner ear morphogenesis; transcription, DNA-dependent; in utero embryonic development; olfactory bulb development; semicircular canal morphogenesis; cranial nerve development; chromatin modification; genitalia development; retina development in camera-type eye; artery morphogenesis; cognition; nose development; rRNA processing
Disease: Charge Syndrome; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Hypogonadotropic Hypogonadism 5 With Or Without Anosmia
Research Articles on CHD7
1. CHD7 mutations are not a major cause of atrioventricular septal and conotruncal heart defects.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
